SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John R. Sashko who wrote (444)3/8/1997 5:43:00 PM
From: I. Luttichuys   of 1762
 
John, As you are a physician you will be in a great position to take advantage of the press releases and some of the information in this thread and especially any info you might recieve by calling Connie at IR for IDEC. Check out the press releases over on Yahoo and (if you have time) read through the posts.
IDEC is not profitable at this time but, as you know, pharmaceutical stocks can perform quite well in spite of this. I don't know who referred you here but, IMO it is an appropriate time to be looking at this issue. IDEC filed a BLA with the FDA recently. Of course we anticipate approval. The trial results will show that this is perhaps not unreasonable. In addition the FDA is under pressure to handle applications for new CA pharmaceuticals in an expedited manner. The FDA appears to have been particularly involved with IDEC's drug (C2B8) at different points in development for this reason. You might check some of Brad Dunlaps recent posts on this topic.
We expect another "strong buy" to be issued on this company soon and IMO it would be late were one to delay until earnings were posted. I feel by that time the stock will be at higher valuations than we are currently seeing. Of course this is my opinion only.
If you hit "quote" and go to "yahoo", under research you will find current earnings estimates etc.
So far, at least from the analysts perspective, we have 12 month targets of $44 and $52.
Please post your further questions or any observations you may have.
BENNETT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News